TP53 and breast carcinoma: Contrastingly, in the patients who had gBRCA2 and TP53 co-mutations, the median age was 45 years compared to 39 years without mutations in TP53. In these patients, the incidence of bilateral breast cancer and node-negative diseases was significantly higher than that with wild type TP53 (p = 0.035 and 0.006, respectively) (Table 1).